Vandetanib induced photoallergic dermatitis: A case report
Abstract
Vandetanib is a multi-kinase inhibitor of epidermal growth factor receptor, vascular endothelial growth factor. Most common dermatological side effects induced by vandetanib include papulopustular eruption, hand-foot syndrome, and hyperpigmentation.
In this report, we present a case with metastatic medullar thyroid carcinoma who developed vandetanib-induced photoallergic dermatitis.
Keywords
References
- 1. Negulescu M, Zerdoud S, Boulinguez S, Tournier E, Delord JP, Baran R, et al. Development of Photoonycholysis with vandetanib Therapy. Skin Appendage Disord. 2017;2:146-51.
- 2. Goldstein J, Patel AB, Curry JL, Subbiah V, Piha-Paul S. Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. BMC Dermatol. 2015;15:2.
- 3. Bota J, Harvey V, Ferguson C, Hood A. A rare case of late-onset lichenoid photodermatitis after vandetanib therapy. JAAD Case Rep. 2015;1:141-3.
- 4. Tokimasa Y, Fujiwara K, Higo H, Kameyama N, Kayatani H, Sato K, et al. Photosensitivity reaction induced by erlotinib. Int Canc Conf J. 2012;1:173.
- 5. Kılıç A. Inhibitors of Epidermal Growth Factor Receptor and Dermatological Side Effects. Turk J Dermatol. 2012;6:168-74.
- 6. Fava P, Quaglino P, Fierro MT, Novelli M, Bernengo MG. Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption. Dermatol Ther. 2010 ;23:553-5.
- 7. Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: Photoallergic and phototoxic reactions. Clin Dermatol. 2016 ;34:571-81.
- 8. Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf. 2007;6:431-43.
Details
Primary Language
English
Subjects
Internal Diseases
Journal Section
Case Report
Publication Date
June 10, 2018
Submission Date
March 26, 2018
Acceptance Date
April 17, 2018
Published in Issue
Year 2018 Volume: 3 Number: 2